Overview

Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects

Status:
Recruiting

Trial end date:
2022-07-01

Target enrollment:

Participant gender:

Summary

A single centre, double-blind, randomized, parallel group, placebo-controlled study in healthy subjects conducted in two parts: Part 1: Single ascending doses in healthy subjects aged 18 to 49 years to assess safety, pharmacokinetics (PK) and pharmacodynamic (PD) effects of VMX-C001. Part 2: Healthy subjects aged 50 to 79 years to assess safety, PK and PD effects of VMX-C001 in the presence of DOACs.

Phase:

Phase 1

Details

Lead Sponsor:

VarmX B.V.

Treatments:

Apixaban
Edoxaban
Rivaroxaban